• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 195

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to the European Public

Psychedelic Medicine at the Edge of Science and Spirit

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin...

Manvir Singh: Shamanism, the Timeless Religion

2025 Year in Review: Future(s) & Open Questions (Video)

Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted...

PT283 – Greg McKee – Nociplastic Pain and Psychedelics

Psychedelic Research and Clinical Trials in 2021

Mydecine Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development...

Stephen Hurst Resigns from MindMed Board of Directors

Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services

Psychedelic Bulletin: Big Pharma’s Foray Into Psychedelics; Psilocybin Trial Makes Headlines;...

Cybin Announces Additional Adelia Milestone Achievement

PT282 – Rabbi Zac Kamenetz & The Rev. Hunt Priest –...

Levitee Labs Announces Medical Advisory Board

1...194195196...305Page 195 of 305

EDITOR PICKS

From Brussels to the Ballot: How PsychedeliCare Took Psychedelic Therapy to...

Psychedelic Medicine at the Edge of Science and Spirit

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©